P&G Hygiene and Health Care
Procter & Gamble Hygiene and Health Care Ltd
- Market Cap
- ₹22,787 Cr
- P/E
- 29.34
Key Fundamentals
SmallcapPersonal ProductsFMCGPrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 157.00%
- Debt to Equity
- 0.00
- EPS (TTM)
- ₹239.27
- Book Value
- ₹272.33
- Market Cap
- ₹22,787 Cr
- P/E (TTM)
- 29.34
- P/B
- 25.78
- ROE
- 115.00%
- Dividend Yield
- 3.68%
- EBITDA
- ₹1,214 Cr
- 52W High
- ₹13,156.00
- 52W Low
- ₹6,579.00
- Day Range
- ₹6,897.50 – ₹7,259.00
- Volume
- 22,680
Peer Comparison
Fast Moving Consumer Goods › Personal Products › Personal Care
| 919.50 | 47.57 | 94,093 | 7.46 | 1.67% | 16.10% | 18.80% | 16,537 | 1,978 | |
| 393.10 | 34.42 | 69,734 | 6.07 | 0.92% | 17.00% | 20.30% | 13,924 | 2,001 | |
| 365.65 | 290.20 | 49,168 | 87.48 | 1.38% | 27.60% | 33.90% | 602 | 169 | |
| 1,760.00 | 35.15 | 47,869 | 29.60 | 1.42% | 82.70% | 108.00% | 6,391 | 1,362 | |
| 7,090.50 | 33.80 | 23,105 | 21.51 | 3.31% | 66.50% | 90.70% | 3,211 | 683 | |
| 7,020.00 | 29.34 | 22,787 | 25.78 | 3.73% | 115.00% | 157.00% | 4,240 | 776 | |
| 422.20 | 24.76 | 18,429 | 6.30 | 1.21% | 26.20% | 28.10% | 4,204 | 747 | |
| Median 7 companies | 919.50 | 34.42 | 47,869 | 21.51 | 1.42% | 27.60% | 33.90% | 4,240 | 776 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 92
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 40
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 30
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 91
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 17
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 38
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
5- Company has reduced debt.
- Company is almost debt free.
- Stock is providing a good dividend yield of 3.28%.
- Company has a good return on equity (ROE) track record: 3 Years ROE 89.4%
- Company has been maintaining a healthy dividend payout of 91.5%
Weaknesses
2- Stock is trading at 25.8 times its book value
- The company has delivered a poor sales growth of 7.40% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 7 | 7 | 5 |
| Oscillators | Bullish | 0 | 7 | 2 |
| Moving Averages | Strong Bearish | 7 | 0 | 3 |
Oscillators
Bullish
Overall
Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 50.13
- Neutral
- MACD (12,26,9)
- −29.61
- Bullish
- SMA (50)
- 7,057.51
- Bearish
- SMA (200)
- 8,981.16
- Bearish
As of
Analyst Rating
2 of 3 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | Irregular period |
|---|---|
| 5Y | Irregular period |
| 3Y | Irregular period |
| 1Y | +27.15% |
| TTM | −2.03% |
Net profit
| 10Y | Irregular period |
|---|---|
| 5Y | Irregular period |
| 3Y | Irregular period |
| 1Y | +34.38% |
| TTM | −6.17% |
Operating cash flow
| 10Y | Irregular period |
|---|---|
| 5Y | Irregular period |
| 3Y | Irregular period |
| 1Y | +54.52% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | Irregular period |
|---|---|
| 5Y | Irregular period |
| 3Y | Irregular period |
| 1Y | +1.48 pp |
| TTM | −1.39 pp |
Revenue by year
| Jun 2017 | ₹2,320 Cr |
|---|---|
| Jun 2018 | ₹2,455 Cr |
| Jun 2019 | ₹2,947 Cr |
| Jun 2020 | ₹3,002 Cr |
| Jun 2021 | ₹3,574 Cr |
| Jun 2022 | ₹3,901 Cr |
| Jun 2023 | ₹3,918 Cr |
| Jun 2024 | ₹4,206 Cr |
| Mar 2025 | ₹3,374 Cr |
| Mar 2026 | ₹4,290 Cr |
Net profit by year
| Jun 2017 | ₹433 Cr |
|---|---|
| Jun 2018 | ₹375 Cr |
| Jun 2019 | ₹419 Cr |
| Jun 2020 | ₹433 Cr |
| Jun 2021 | ₹652 Cr |
| Jun 2022 | ₹576 Cr |
| Jun 2023 | ₹678 Cr |
| Jun 2024 | ₹675 Cr |
| Mar 2025 | ₹637 Cr |
| Mar 2026 | ₹856 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Procter & Gamble Hygiene and Health Care Ltd trades at ₹6,988.50 as of 2026-11-17 with a market cap of ₹22,685 crore. The company is virtually debt-free with an exceptionally high ROE of 113.67% and ROCE of 135.44%, but the stock has declined 46% over the past year and currently trades 47% below its 52-week high of ₹13,156, while TTM sales and profit growth have turned negative.
- The company is essentially debt-free with a debt-to-equity ratio of 0, providing significant financial flexibility and resilience across economic cycles.
- ROE stands at an extraordinary 113.67% as of 2026-11-17, with a 3-year average ROE of 89% and last year's ROE at 115%, indicating highly efficient capital utilisation.
- ROCE of 135.44% reflects exceptional returns on total capital employed, among the highest in the FMCG sector.
- Dividend yield of 3.71% as of 2026-11-17 is notably generous for an FMCG company, supported by a healthy dividend payout ratio of 91.5%.
- Compounded profit growth of 14% over both 3-year and 5-year periods demonstrates a sustained earnings trajectory despite recent softness.
- The stock trades at ₹6,988.50, just 6% above its 52-week low of ₹6,579, which may indicate that much of the negative sentiment is already reflected in the price.
- Backed by a global FMCG parent with deep expertise in hygiene and health care categories, the company operates in segments with structural long-term demand in India.
- The stock is trading at 25.66 times book value as of 2026-11-17, an elevated valuation that leaves little margin for error.
- TTM sales growth has turned negative at -2%, a sharp deceleration from the 5-year compounded sales growth of 7% and 10-year rate of 6%.
- TTM profit growth is -6%, reversing the positive trend seen over the 3-year (14%) and 5-year (14%) compounding periods.
- The stock has delivered a 1-year return of -46% and a 10-year CAGR of just 1%, indicating prolonged destruction of shareholder value relative to broader market returns.
- Five-year sales CAGR of 7% is modest for a consumer goods company operating in a high-growth emerging market like India.
- The stock has fallen 47% from its 52-week high of ₹13,156 to ₹6,988.50, reflecting a severe de-rating and loss of market confidence.
- Even the 3-year and 5-year stock CAGRs are deeply negative at -28% and -14% respectively, suggesting structural concerns beyond short-term earnings volatility.
- A PE of 29.21 on TTM earnings, while the company is experiencing negative top-line and bottom-line growth, suggests the valuation may not yet fully account for the earnings slowdown.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: A quiet period for P&G Hygiene with no major operational news. The resolution of a long-pending transfer pricing dispute (FY11-FY19) is a net positive, trimming contingent liabilities by ₹94 crore at a cost of just ₹14.3 crore. No fresh headwinds have emerged. Watch for upcoming quarterly results and any demand commentary in the FMCG space for forward direction.
- Contingent liabilities cut ₹94Cr Nov 17
P&G Hygiene settled a transfer pricing dispute covering FY11-FY19, reducing contingent liabilities by ₹94 crore — a meaningful cleanup of the balance sheet.
- TP settlement costs ₹14.3Cr Nov 17
The settlement required a one-time payment of ₹14.3 crore to resolve the transfer pricing dispute, a modest outflow relative to the ₹94 crore reduction in contingent liabilities.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,138 | 1,133 | 1,002 | 932 | 1,135 | 1,248 | 992 | 937 | 1,150 | 1,262 | 941 | 891 | 1,145 |
| Expenses | 853 | 824 | 745 | 813 | 845 | 877 | 782 | 671 | 865 | 860 | 723 | 721 | 885 |
| Operating Profit | 285 | 310 | 257 | 118 | 290 | 371 | 210 | 266 | 285 | 402 | 218 | 170 | 260 |
| OPM % | 25% | 27% | 26% | 13% | 26% | 30% | 21% | 28% | 25% | 32% | 23% | 19% | 23% |
| Other Income | 16 | 16 | 14 | 7 | 8 | 10 | 19 | 8 | 10 | 12 | 12 | 9 | 17.01 |
| Interest | 2 | 3 | 22 | 0 | 2 | 7 | 6 | 0 | 4 | 3 | 3 | 0 | 3.67 |
| Depreciation | 14 | 14 | 15 | 13 | 12 | 10 | 10 | 9 | 9 | 10 | 10 | 10 | 11.44 |
| PBT | 284 | 309 | 234 | 112 | 285 | 364 | 213 | 265 | 282 | 402 | 218 | 170 | 262 |
| Tax % | 26% | 26% | 34% | 28% | 26% | 26% | 27% | 27% | 26% | 25% | 30% | 26% | 25% |
| Net Profit | 211 | 229 | 154 | 81 | 212 | 269 | 156 | 192 | 210 | 301 | 153 | 126 | 196 |
| EPS (₹) | 64.91 | 70.52 | 47.56 | 24.97 | 65.28 | 82.74 | 48.09 | 59.17 | 64.65 | 92.87 | 47.17 | 38.90 | 60.33 |
| YoY Sales growth | 9 | 0 | 13 | 9 | 0 | 10 | −1 | 1 | 1 | 1 | −5 | −5 | 0 |
Profit & Loss
₹ Cr| Particulars | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,334 | 2,275 | 2,320 | 2,455 | 2,947 | 3,002 | 3,574 | 3,901 | 3,918 | 4,206 | 3,374 | 4,290 | 4,240 |
| Expenses | 1,838 | 1,667 | 1,646 | 1,834 | 2,329 | 2,396 | 2,688 | 3,069 | 3,048 | 3,230 | 2,503 | 3,119 | 3,189 |
| Operating Profit | 495 | 608 | 675 | 622 | 618 | 606 | 886 | 832 | 869 | 976 | 871 | 1,171 | 1,050 |
| OPM % | 21% | 27% | 29% | 25% | 21% | 20% | 25% | 21% | 22% | 23% | 26% | 27% | 25% |
| Other Income | 64 | 85 | 67 | 18 | 45 | 42 | 39.38 | 23 | 40.58 | 47 | 37 | 42 | 51 |
| Interest | 6 | 6 | 10 | 5 | 5 | 6 | 6 | 11 | 11 | 27 | 14 | 9 | 10 |
| Depreciation | 53 | 52 | 60 | 52 | 50 | 48 | 48 | 53 | 58 | 56 | 32 | 37 | 40 |
| PBT | 501 | 636 | 672 | 582 | 607 | 594 | 870 | 790 | 839 | 939 | 862 | 1,167 | 1,052 |
| Tax % | 31% | 34% | 36% | 36% | 31% | 27% | 25% | 27% | 19% | 28% | 26% | 27% | — |
| Net Profit | 346 | 422 | 433 | 375 | 419 | 433 | 652 | 576 | 678 | 675 | 637 | 856 | 777 |
| EPS (₹) | 106.63 | 130.16 | 133.31 | 115.40 | 129.12 | 133.42 | 200.79 | 177.37 | 208.91 | 207.95 | 196.11 | 263.86 | 239.27 |
| Div. Payout % | 28% | 28% | 292% | 35% | 68% | 79% | 157% | 90% | 89% | 123% | 89% | 97% | — |
| Sales growth | 14 | −2 | 2 | 6 | 20 | 2 | 19 | 9 | 0 | 7 | −14 | 27 | −2 |
Balance Sheet
₹ Cr| Particulars | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 |
| Reserves | 1,196 | 1,619 | 494 | 773 | 877 | 1,125 | 682 | 705 | 914 | 742 | 705 | 721 | 852 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 4 | 3 | 2 | 1 | 0 |
| Other Liabilities | 719 | 515 | 634 | 620 | 708 | 671 | 915 | 940 | 1,187 | 1,081 | 1,015 | 1,049 | 1,245 |
| Total Liabilities | 1,948 | 2,166 | 1,160 | 1,425 | 1,617 | 1,828 | 1,633 | 1,683 | 2,137 | 1,859 | 1,755 | 1,804 | 2,129 |
| Fixed Assets | 309 | 317 | 286 | 250 | 234 | 206 | 184 | 164 | 170 | 139 | 131 | 163 | 163 |
| CWIP | 39 | 35 | 41 | 21 | 15 | 22 | 38 | 44 | 23 | 28 | 41 | 21 | 28 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,600 | 1,814 | 834 | 1,154 | 1,368 | 1,600 | 1,411 | 1,475 | 1,945 | 1,692 | 1,583 | 1,619 | 1,939 |
| Total Assets | 1,948 | 2,166 | 1,160 | 1,425 | 1,617 | 1,828 | 1,633 | 1,683 | 2,137 | 1,859 | 1,755 | 1,804 | 2,129 |
Cash Flow
₹ Cr| Particulars | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 426 | 352 | 445 | 415 | 413 | 474 | 863 | 573 | 826 | 470 | 598 | 924 |
| Investing | 28 | 221 | 149 | −19 | 34 | 75 | 7 | −27 | −10 | 1 | −34 | 11 |
| Financing | −105 | −122 | −1,559 | −106 | −314 | −190 | −1,106 | −569 | −477 | −861 | −671 | −845 |
| Net Cash Flow | 349 | 452 | −964 | 290 | 134 | 358 | −236 | −23 | 339 | −390 | −107 | 91 |
| Free Cash Flow | 348 | 300 | 401 | 377 | 410 | 423 | 832 | 523 | 781 | 427 | 544 | 893 |
| CFO/EBITDA | 127 | 91 | 103 | 111 | 105 | 102 | 126 | 99 | 121 | 79 | 96 | 105 |
Ratios
| Particulars | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 18 | 24 | 21 | 22 | 22 | 20 | 15 | 18 | 20 | 21 | 33 | 21 |
| Inventory Days | 47 | 53 | 71 | 48 | 60 | 68 | 78 | 55 | 48 | 51 | 64 | 51 |
| Days Payable | 148 | 134 | 145 | 156 | 162 | 175 | 237 | 183 | 213 | 193 | 235 | 197 |
| Cash Conversion Cycle | −83 | −57 | −53 | −87 | −79 | −87 | −144 | −110 | −145 | −121 | −138 | −126 |
| Working Capital Days | 4 | 8 | −15 | −23 | −12 | −21 | −39 | −34 | −53 | −32 | −30 | −31 |
| ROCE % | 46% | 45% | 64% | 89% | 73% | 58% | 94% | 110% | 101% | 112% | 104% | 157% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view P&G Hygiene and Health Care insights
63 extracted metrics across FY11–FY27.
Documents
- Concall · Jun 2026Transcript PPT Recording
- Concall · Jun 2025Transcript PPT Recording
- Concall · Sep 2024Transcript PPT
- Concall · Sep 2023Transcript PPT
- Concall · Mar 2019PPT
- General announcements 17 Nov 2026
- General announcements 17 Nov 2026
- General announcements 12 Nov 2026
Frequently Asked Questions about P&G Hygiene and Health Care
What does Procter & Gamble Hygiene and Health Care Ltd do?
Where is Procter & Gamble Hygiene and Health Care Ltd (PGHH) listed?
Which sector does Procter & Gamble Hygiene and Health Care Ltd belong to?
What is the market capitalisation of Procter & Gamble Hygiene and Health Care Ltd?
What is the PE ratio of Procter & Gamble Hygiene and Health Care Ltd?
What is the 52-week high and low of Procter & Gamble Hygiene and Health Care Ltd?
Does Procter & Gamble Hygiene and Health Care Ltd pay dividends?
What is the Return on Equity (ROE) of Procter & Gamble Hygiene and Health Care Ltd?
Company Information
Procter & Gamble Hygiene and Health Care Limited is engaged in the manufacturing and selling of branded packaged fast moving consumer goods in the femcare and healthcare businesses. Its portfolio includes WHISPER – India’s leading Feminine Hygiene brand, and VICKS – India’s No. 1 Health Care brand and Old Spice.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PGHH.md for Procter & Gamble Hygiene and Health Care Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.